Pfizer Financial News

Gilead Sciences, a biotech company focused on treatments for cancer and HIV, isn’t pitching itself as an obesity drug developer. But that hasn’t stopped some Wall Street analysts from trying to do that on its behalf. Seasoned Jefferies analyst Michael Yee published a market-moving note to investors last week: He dug up recent patents and cross-referenced them with prior data to unearth what looked like the makings of an early-stage metabolic program that could one day become an obesity program.

Also Read- Suven Pharmaceuticals share price rises 5% on CDMO Sapala Organics acquisitionDuring May'2024, among the top-20 pharma companies, Glenmark Pharmaceuticals with growth of 18.9% yar-on-year) and JB Pharma with a growth of 13.1% YoY grew at a significantly faster pace (in the listed space) compared to the IPM, suggested Motilal Oswal Financial Services data.Ajanta Pharma with 12.3% year-on-year growth, Zydus Lifesciences with 11.8% growth and Mankind Pharma with 10.8% growth and Cipla with 10.1% growth were among other outperformers in the listed space.Among MNCs Sanofi India with 12.2% growth also stood out and was among significant outperformers. However among key underperformers during the month stood Pfizer, Indoco Remedies, GSK (Glaxosmithkline Pharma), IPCA Laboratories and Alembic, which posted 1-7% yoy growth , suggested analysts data.Among the top-25 companies, Torrent Pharmaceuticals, Abbott, Lupin, JB Pharma and Zydus have gained maximum share over the past six months in the listed space, said analysts at Kotak Institutional Equities.

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday. Lorlatinib, which is already approved and available under the brand name Lorbrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Roughly half received lorlatinib while the rest received crizotinib, an earlier generation drug.

Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said.

GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors. The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley's plans to boost earnings at the drugmaker.

pharma giant Pfizer, recently claimed that ‘I am not suicidal’ and if anything happens to her the government and Big Pharma are to blame. The news is concerning as it comes only days after demise of the second Boeing whistleblower. McAtee posted a video on X where she is seen saying, "Hello everybody.

cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. «A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study,» a company spokesperson told Reuters in an emailed response.

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by brothers Felix and Julian Baker, had in 2003 invested in Seagen, a developer of next-generation cancer treatments.

Gland Pharma Ltd.(up 4.74 per cent), Glenmark Pharmaceuticals Ltd.(up 2.42 per cent), Torrent Pharmaceuticals Ltd.(up 1.57 per cent), GlaxoSmithKline Pharmaceuticals Ltd.(up 1.32 per cent) and Cipla Ltd.(up 1.08 per cent) were among the top gainers.

Investing.com — U.S. futures slipped lower Tuesday, amid caution ahead of the start of an eagerly-awaited Federal Reserve policy-setting meeting.

(Reuters) -Consumer healthcare firm Haleon said on Monday that U.S. drugmaker Pfizer (NYSE:PFE) will sell down its stake in the company to about 24%.

Shares of Pfizer Ltd.(up 2.89 per cent), Gland Pharma Ltd.(up 2.36 per cent), Alkem Laboratories Ltd.(up 1.21 per cent), Abbott India Ltd.(up 0.35 per cent) and Laurus Labs Ltd.(up 0.08 per cent) ended the day as top gainers in the pack.

By Brendan Pierson

Health officials are investigating whether there's a link between two new RSV vaccines and cases of a rare nervous system disorder

World markets today: US stocks dip ahead of inflation data Adani Power, Indian Railway Finance Corporation, Jio Financial Services, Power Finance Corporation, and REC Ltd have also joined the Nifty Next 50 index. Conversely, Adani Wilmar, Muthoot Finance, PI Industries, Procter & Gamble Hygiene & Health Care, and Shriram Finance have been removed from the index.

tax benefit is spurring US companies including PepsiCo Inc. and International Business Machines Corp. to sell bonds through their Singapore subsidiaries, fueling a record surge of sales from borrowers in the city state. The tactic can allow companies to deduct interest expense from their taxable income in both the US and Singapore. That double deduction means that effective borrowing costs — after taxes — can be materially lower than they would be with a bond issued in the US.

Also Read-Glenmark Pharma share price jumps over 6% after Q3 result Bulk of the IPM growth in January 2024 was largely driven by therapies such as immunomodulators, hepatoprotectives, antivirals, cardiac and urology. However the softer growth rate in acute range is also attributed to high base and seasonal factors in January.

Hero MotoCorp: India’s largest two-wheeler maker’s profits zipped into high-growth territory in the December quarter. Hero MotoCorp saw a 51% year-on-year jump in its net profit at ₹1,073 crore in the third quarter, mirroring the lift in profits and volumes seen by listed peers Bajaj Auto & TVS Motor Company. The company also reported a 21% increase in revenue from operations to ₹9,723.73 crore in Q3FY24, versus ₹8,030.98 crore in Q3FY23.

₹130 crore ( ₹129.98 crore). The company had reported a net profit of ₹150.66 crore in Q3 FY23.

Shares of Biocon Ltd.(up 2.32 per cent) and Alkem Laboratories Ltd.(up 0.46 per cent) ended the day as top gainers in the pack. On the other hand, Aurobindo Pharma Ltd.(down 2.68 per cent), Divi's Laboratories Ltd.(down 2.44 per cent), Glenmark Pharmaceuticals Ltd.(down 2.34 per cent), Pfizer Ltd.(down 2.11 per cent) and Natco Pharma Ltd.(down 1.97 per cent) finished as the top losers of the day.